Please ensure Javascript is enabled for purposes of website accessibility

Is There Any Hope Left for This Alzheimer's Drug Developer?

By Taylor Carmichael – Aug 13, 2021 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biogen is reeling from charges that its drug doesn't work.

In a surprise move, the Food and Drug Administration approved the new Alzheimer's drug from Biogen (BIIB 4.72%), even though the drug failed to beat placebo in its clinical trials. The company has also come under sharp attacks for trying to get Medicare and health insurers to pay $56,000 for each patient on the drug. There are over 6 million Alzheimer's patients, just in the U.S. Already the Department of Veterans Affairs has declined to pay for Biogen's drug, citing both its lack of efficacy and safety concerns.  

Olivia Zitkus, an analyst and editor at the Motley Fool, and Fool contributor Taylor Carmichael spoke on the issue during this episode of Motley Fool Live, recorded on July 30.

 

10 stocks we like better than Biogen
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and Biogen wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 9, 2021

 

Olivia Zitkus: Taylor, if it's cool with you, I think I want to kick off our discussion with the stock that everyone loves to hate lately, Biogen. There's been a lot of news around its drug Aduhelm, which was approved by the FDA as a treatment for Alzheimer's disease on June 7. It's since had a label update and controversy has whirled so much so that the R&D chief of Biogen released a letter directly to the Alzheimer's community on the day of the Q2 earnings release, July 22. I will read a portion of that just to color what we're going to talk about. Here we go from the R&D chief:

Unfortunately, Aduhelm's approval has been the subject of extensive misinformation and misunderstanding. It is normal for scientists and clinicians to discuss data from experiments in clinical trials, to debate and to disagree on the interpretation of data. That is how science advances and we welcome these discussions. Recently, however, there has been a turn outside the boundaries of legitimate scientific deliberation.

Taylor, I'd love to get your reaction to the R&D chief's response. Then I'll ask your thoughts on Aduhelm and FDA decision itself. But what are your thoughts on this?

Taylor Carmichael: I thought it was really interesting that they had the R&D chief write this letter -- that's my dog -- instead of the CEO. [laughs]

Zitkus: He's not a fan. [laughs]

Carmichael: She doesn't like it. A couple of interesting things. One, the most controversial thing about Biogen, I think, is the price points they are doing, not so much -- I mean, there are two levels of controversy. There's controversy about the drug being approved. It was very controversial among scientists in particular. But it's also controversial because they're charging $56,000. There's 6 million patients with Alzheimer's just in the U.S. In the world, it's a great deal higher. If everybody were to be prescribed a $56,000 drug, it would be hundreds of billions of dollars. Kind of an insane price point, kind of a niche price point and it just raises more questions about this drug. What the FDA did, they approved this drug based on biomarkers, in that, Alzheimer's patients have plaques in the brain. What this drug does is reduce those plaques. The theory is, if you reduce those plaques, and they're amyloid, I think is the name, amyloid plaques.

Zitkus: Yes, amyloid plaques.

Carmichael: If you reduce those plaques, the theory is that Alzheimer's patients will stop getting worse. Hasn't borne out. I'm not a medical doctor, but my own opinion, this is a bad theory. This is a culmination of decades of failure trying to go along this route of getting rid of these plaques. But what the FDA did, they approved it because it is reducing the plaques in the brain, even though they are seeing no improvement or significant efficacy in the drug in terms of patients welfare or getting better. That was highly controversial. Every doctor on their advisory panel said, "You should not approve this drug," and the FDA approved it. That was controversial. The head of the FDA who was not involved in that decision has called for an investigation into why it was approved. It's been highly controversial even in the FDA. The FDA has been attacked for approving this drug. People have been waiting for a new Alzheimer's treatment for a long time, so to have a $56,000 price point in a drug where all the doctors on the advisory committee said, "Don't approve it," the whole thing seems incredibly sketchy --

Zitkus: Right.

Carmichael -- and bewildering.

Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Stock Quote
Biogen
BIIB
$305.17 (4.72%) $13.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.